Processa appoints James R. Neal, CEO of XOMA, to board of directors

Processa Pharmaceuticals, Inc.

James R. Neal appointed to Processa Board effective July 19, 2022.
Neal is CEO and Chairman of XOMA; also on board of Palisade Bio and Monterey Bio Acquisition.
Appointment brings life sciences and public company experience to Processa board.
Neal will be compensated as per non-employee director program described in May 31, 2022 proxy statement.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

James R. Neal

Board of Directors

PCSA · Processa Pharmaceuticals, Inc.

Effective: 2022-07-19
Filed: July 25, 2022, 7:59 PM ET

On July 19, 2022, the Board of Directors of Processa Pharmaceuticals, Inc. (the “Company”) appointed James R. Neal to its Board of Directors, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James R. Neal was appointed as Board of Directors at Processa Pharmaceuticals, Inc..

Action: appointed
Role: Board of Directors

Exact text from the filing

On July 19, 2022, the Board of Directors of Processa Pharmaceuticals, Inc. (the “Company”) appointed James R. Neal to its Board of Directors, effective immediately.

View on SEC.gov

Processa Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-020258

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.